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no radiological evidence of OA (KL<2). The longitudinal data was analyzed
using generalized least squares adjusted to JSN score and height with a
covariance structure grouped by subject and using time as continuous
covariate.
Results: From the 133 analyzed subjects, 18 subjects met the analysis
criteria (KL<2). Table 1 shows the results of the quantitative analysis of
change.
Conclusions: Our results show that a signiﬁcant proportion (74% to 83%)
of subjects with frequent knee pain and stiffness and KL scores lower than
2 had statistically signiﬁcant changes in articular cartilage thickness at
the WB regions. Based on these results subjects with OA symptoms but
no radiographic evidence of OA may be staged and monitored for disease
progression. The SRM of the mean on the order of 0.8 allows the design of
clinical trials of reasonable size for this kind of population.
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A DECREASE IN SERUM LEVEL OF MATRIX METALLOPROTEASES IS
PREDICTIVE OF A DRUG’S DMOAD EFFECT ASSESSED BY QUANTITATIVE
MRI IN KNEE OSTEOARTHRITIS PATIENTS
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Purpose: To explore in a Phase III clinical trial in knee osteoarthritis (OA)
patients, the impact of disease-modifying OA drug (DMOAD) treatment on
biomarker levels.
Methods: 161 knee OA patients (according-to-protocol population) were
selected from a two-year DMOAD trial studying the effect of licofelone
(200 mg bid) versus naproxen (500 mg bid). MRI was done at baseline
and two years. Patients underwent clinical evaluation using the WOMAC
questionnaire. Seven OA biomarkers were measured at baseline and two
years: MMP-1, MMP-3, IL-6, CRP, COMP, and CTX-I in serum, and CTX-II in
urine.
Results: Over time an increase in all biomarker levels was found with
the exception of IL-6, CRP, and CTX-II, which decreased. The increase
in MMP-1 and MMP-3 was signiﬁcantly less (p<0.05; p<0.0001) in the
licofelone than the naproxen group. The MMP-1 level at baseline was a
signiﬁcant predictor (inverse correlation) of cartilage volume change for the
medial compartment (univariate, p=0.043; multivariate regression analysis,
p=0.038) and COMP, a positive predictor for the lateral compartment
(univariate p<0.0001; multivariate p<0.002). IL-6 and CRP also presented
a signiﬁcant relation to the volume change for the medial compartment
but only in the univariate model (p=0.038 and p=0.007, respectively). A
signiﬁcant association was observed in the univariate model between the
change in the level of MMP-1 (p=0.034), MMP-3 (p=0.019), and cartilage
loss (lateral compartment) over two years. Baseline levels of CTX-I cor-
related (p=0.02) with increase in bone marrow lesion size in the medial
compartment. The CRP levels at baseline correlated positively with wors-
ening of symptoms: WOMAC total index (p=0.0009), pain (p=0.002) and
function (p=0.001).
Conclusions: This study demonstrated that higher baseline values of IL-6,
CRP, and COMP were predictive of a greater risk of OA cartilage loss. How-
ever, over time a reduction in the MMP-1 and MMP-3 levels correlated best
with a reduction in the loss of cartilage and the effect of drug treatment.
The baseline CRP was found to be a good predictor of the symptomatic
response to treatment.
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DISEASE
I. Rego-Perez1 , M. Fernandez-Moreno1, M. Deberg2, S. Pertega3,
C. Fernandez-Lopez1, N. Oreiro1, M. Acasuso4, V. Bonome-Gonzalez5,
Y. Henrotin2, F.J. Blanco1
1Osteoarticular and Aging Res. Lab. Rheumatology Div. INIBIC-Complejo Hosp.
Univ. A Coruña, A Coruña, Spain; 2Bone and Cartilage Res. Unit. Univ. of Liege,
Liege, Belgium; 3Epidemiology Unit. INIBIC-Complejo Hosp. Univ. A Coruña, A
Coruña, Spain; 4Centro de Salud San José - SERGAS, A Coruña, Spain; 5Centro
de Salud Matogrande - SERGAS, A Coruña, Spain
Purpose: Recent evidences led to the conclussion that mitochondria me-
diate in the pathogenesis of the osteoarthritis (OA). Biomarkers are a
promising tool to detect patients with OA preferably in an early stage of the
disease. In this work we aim to assess a mitochondria-related phenotype in
patients with OA.
Methods: We analyzed the results from our previous determinations of
serum levels of several OA-related biomarkers such as MMP-1, MMP-3,
MMP-13, MPO, Coll2-1 Coll2-1NO2, C2C, CPII, hyaluronic acid, YKL-40,
COMP and cathepsin K, in 48 OA patients and 52 healthy controls carrying
the haplogroups H and J, to perform logistic regression models and receiver
operating characteristic (ROC) curves that permit us to predict diagnosis
of OA. This models also included clinical variables such as gender, age and
smoking status.
Results: The MMP-13 was the only biomarker signiﬁcantly increased in
OA patients, when compared with healthy controls, in both mtDNA hap-
logroups H and J (p<0.001). Type II collagen biomarkers such as Coll2-1,
Coll2-1NO2, Coll2 ratio, C2C, CPII and C2C:CPII ratio were signiﬁcantly
increased in OA patients that carry the mtDNA haplogroup H when com-
pared with OA carriers of the mtDNA haplogroup J (p<0.01 in all cases).
Two logistic regression models for diagnosis, adjusted for age, gender and
smoking status, were constructed. For haplogroup H, the regression model
obtained showed that the biomarkers signiﬁcantly associated with OA were
hyaluronic acid and C2C:CPII; the area under the curve (AUC) of the ROC
curve for this model was 0.926 (95% CI=0.857-0.995) and the optimal prob-
ability cutoff for discriminate between OA and healthy controls was 0.269,
with a sensitivity of 96%, a speciﬁcity of 78%, and a positive likelihood
ratio of 4.3. For haplogroup J, the biomarkers signiﬁcantly associated with
OA were MMP-13, MMP-3 and C2C; the AUC for this model was 0.880
(95% CI=0.782-0.978), and the optimal probability cutoff for discriminate
between OA patients and healthy controls was 0.271, with a sensitivity of
96%, a speciﬁcity of 68%, and a positive likelihood ratio of 3.
Conclusions: The MMP-13 appears to be a good candidate diagnosis
biomarker for OA. Some of the OA-related biomarkers clearly show a
different proﬁle depending on the mtDNA haplogroup. This permitted us to
perform two models of diagnosis of OA haplogroup-based.
115
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Purpose: Obesity is a major risk factor of osteoarthritis. The link between
obesity and osteoarthritis (OA) may be explained by the increased joint
stress accompanying obesity. However, it does not explain why being
obese is also associated with osteoarthritis in non-weight-bearing joints,
such as the hands. It is suggested that systemic products of fat with
systemic metabolic activity may inﬂuence the onset and/or progression of
osteoarthritis. We investigated here the association between three most
common adipokines: leptin, adiponectin and resistin and the progression
of hand osteoarthritis.
Methods: We selected patients with radiographic hand OA (HOA) from the
GARP (Genetic ARthrosis and Progression) cohort. In this cohort, Caucasian
sibs with predominantly symptomatic OA at multiple sites were included.
We deﬁned HOA as Kellgren and Lawrence score ≥2 in at least two
from 20 hand joints (four proximal interphalangeal joints (PIP’s), four
distal interphalangeal joints (DIP’s), one interphalangeal (IP-1) and one
carpometacarpal (CMC-1) on each hand). Using the Osteoarthritis Research
Society International atlas, the baseline and 6-years follow-up radiograph
were assessed for the joint space narrowing (JSN, grade 0 to 3: 0 normal,
3: severe narrowing) of 20 joints (four DIP’s, four PIP’s, one IP-1 and one
CMC-1) per patient. JSN reﬂects articular cartilage damage. The radiographs
were assessed by two readers in consensus and the intra-class correlation
coeﬃcient for intra-reader reproducibility based on 25 randomly selected
pairs of radiographs was high (0.87). Progression was deﬁned as a change
in JSN above the smallest detectable change (SDC) of 2, reﬂecting change
above measurement error. Baseline serum adiponectin concentration was
measured by Bio-Plex Pro Assay (Bio-Rad, USA). With logistic regression
analysis odds ratios of hand osteoarthritis progression were computed and
transformed to risk ratio (RRs). Adjustments for confounders as age, sex,
body mass index (BMI) and family effect were made. We categorized all
adipokines in tertiles.
Results: Of 248 included patietns, complete follow-up data were available
Poster Presentations / Osteoarthritis and Cartilage 18, Supplement 2 (2010) S45–S256 S59
from 164 patients (66%, mean age [SD]: 60 [7] years, 81% female, mean
BMI [SD]: 27 [5] kg/m2). Fifety-ﬁve patients showed hand OA progression.
BMI was positively correlated with leptin (Pearson’s correlation coeﬃcient,
r=0.3) and resistin (r=0.2) and negatively correlated with adiponectin
(r=-0.2). Leptin, adiponectin and resistin did not signiﬁcantly correlate to
each other. BMI was not associated with radiographic hand OA progression
(β-regression coeﬃcient -0.04 (95% conﬁdence interval -0.08 to 0.05). The
association between adipokines and progression of osteoarthritis is shown
in Table 1.
Table 1. Association between adipokines and progression of hand osteoarthritis
Adiponectin Risk Ratio (95% CI) Risk Ratio (95% CI) after
adjustment for age, sex, BMI and family effect
Leptin (ng/mL)
<4.4 1 (reference) 1 (reference)
4.41 to 8.2 0.7 (0.3 to 1.6) 0.7 (0.3 to 1.5)
>8.2 1.1 (0.5 to 2.3) 1.2 (0.4 to 2.5)
Adiponectin (μg/mL)
<16.6 1 (reference) 1 (reference)
16.6 to 28.4 0.3 (0.1 to 0.7) ‡ 0.2 (0.1 to 0.5) ‡
>28.4 0.3 (0.1 to 0.6) ‡ 0.2 (0.1 to 0.5) ‡
Resistin (ng/mL)
<0.8 1 (reference) 1 (reference)
0.8 to 1.4 1.0 (o.4 to 2.1) 0.9 (0.4 to 1.8)
>1.4 0.8 (0.4 to 1.7) 0.7 (0.3 to 1.5)
CI: Conﬁdence Interval.
Conclusions: We show for the ﬁrst time a substantial inverse association
between serum adiponectin levels and radiographic worsening of hand
osteoarthritis. Further studies on the use of adiponectin as biological
markers for osteoarthritis progression and studies on the biological role of
adiponectin in osteoarthritis are needed.
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SERUM BIOMARKER STUDIES OF SYMPTOMATIC SUBJECTS WITH
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Purpose: To contrast serum biomarker levels in population-based cohorts
asymptomatic for knee pain and symptomatic for knee pain.
Methods: Subjects, 40-79 years, with knee pain (n=255) were recruited
as a random population sample in a study to evaluate early knee os-
teoarthritis (OA) (MoDEKO study). Subjects, 40-79 years, without knee
pain (n=80) were recruited as a random sample of the same population.
For the symptomatic cohort, subjects were included if, in at least one
knee, they had 1) pain in or around the knee on most days of the
month at any time in the past; and, 2) any pain in or around the knee
during the past year. In the asymptomatic cohort, subjects were included
if they responded ‘no’ to both pain questions for both knees. OA status
was assessed on magnetic resonance imaging (MRI) (1.5T) with cartilage
graded from 0-4 (0=normal, 1=hyperintense signal, 2=less than 50% defect,
3=50-100% defect, 4=100% defect). Twenty-three serum biomarkers were
measured in both cohorts, including matrix metalloproteinases (MMPs) 1,
3 and 9, tissue inhibitor of MMP (TIMP-1), interleukins (IL) 1a, 1b, 4, 6,
7, 8, 10, 17A, tumor necrosis factor alpha, c-telopeptide of type I collagen
(CTX-I), adiponectin, resistin, eotaxin, C-reactive protein (CRP), hyaluronic
acid (HA), cartilage oligomeric matrix protein (COMP) and chemokines.
Means of log transformed biomarkers were compared in symptomatic vs
asymptomatic cohorts using 2-sample t-tests. Analyses were adjusted for
stratum sampling weights.
Results: In the symptomatic and asymptomatic cohorts, 56.3% and 56.5%
were female, mean age was 56.7 and 54.6 years, mean BMI was 26.5 and
25.4, respectively. MRI abnormalities ≥ grade 1 were seen in 91% of symp-
tomatic and 67.5% of asymptomatic subjects. No signiﬁcant differences in
biomarker levels in asymptomatic vs symptomatic cohorts were seen for
adiponectin, CTX-I, MMP-1, MMP-3, COMP and HA (Table 1). Statistically
Table 1. Mean (SD) of select log-transformed serum biomarkers in symptomatic and
asymptomatic cohorts
Biomarker Symptomatic cohort Asymptomatic cohort p-value
(n=255) (n=80)
Adiponectin 3.08 (0.36) 3.01 (1.30) 0.47
CRP 1.76 (0.79) 1.31 (2.30) 0.009
CTX-I -1.41 (0.36) -1.23 (1.35) 0.05
IL-4 2.65 (1.58) -3.54 (2.89) <0.001
IL-10 1.25 (1.25) -2.45 (2.71) <0.001
IL-1b 0.20 (0.84) -2.62 (1.75) <0.001
MMP-1 2.85 (0.39) 2.72 (1.18) 0.15
MMP-3 2.59 (0.27) 2.68 (1.08) 0.21
MMP-9 5.67 (0.28) 6.00 (0.82) <0.001
Resistin 2.23 (0.26) 3.10 (0.73) <0.001
TIMP-1 5.13 (0.13) 5.01 (0.32) <0.001
TNF alpha 2.54 (0.66) -2.59 (0.69) <0.001
COMP 7.39 (0.11) 7.36 (0.51) 0.36
HA 3.61 (0.41) 3.63 (1.27) 0.83
signiﬁcant differences were seen for all other biomarkers, including CRP,
eotaxin, interleukins, MMP-9, TIMP-1, TNF alpha, resistin and chemokines.
Conclusions: Serum biomarkers for inﬂammation, especially involving pro-
inﬂammatory and regulatory cytokines, are the key distinguishing feature
between those with symptomatic knee pain and those without. This sug-
gests that alterations in innate immunity are associated with persistent
knee pain, in view of the absence of convincing evidence in the literature
for adaptive immunity in OA.
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THE ASSOCIATION BETWEEN SYNOVIAL FLUID LEVELS OF AGGRECAN
ARGS FRAGMENTS AND RADIOGRAPHIC PROGRESSION OF KNEE
OSTEOARTHRITIS
S. Larsson1, M. Englund1,2, A. Struglics1, S. Lohmander1
1Lund Univ., Dept. of Orthopaedics, Clinical Sci. Lund, Lund, Sweden; 2Boston
Univ. Sch. of Med., Clinical Epidemiology Res. & Training Unit, Boston, MA
Purpose: Aggrecanase cleavage at the Glu-Ala bond in the interglobular
domain of aggrecan, releasing N-terminal ARGS fragments, is an early key
event in arthritis and joint injuries. We have previously shown that synovial
ﬂuid levels of ARGS (SF ARGS) are elevated early after knee injury and in
arthritis. Here we investigate whether SF ARGS levels distinguish subjects
with progressive radiographic knee osteoarthritis (ROA) from those with
stable or no ROA.
Methods: We studied 141 subjects whom at examination A had undergone
meniscectomy some 18 years earlier. Seventeen un-operated individuals
without injury to the meniscus or ligaments were used as references. At
examinations A and B, with a mean follow up time of 7.5 years, we obtained
SF and standing tibiofemoral and skyline patellofemoral radiographs. SF
ARGS was measured by a sandwich immunosorbent electrochemilumines-
cence assay using an anti-aggrecan antibody (AHP0022; Invitrogen) for
capture, and a monoclonal anti-ARGS (OA-1) for detection. Radiographs
were graded according to the OARSI atlas. The association between levels
of SF ARGS at examination A and progression of radiographic features
of knee OA between examinations A and B were assessed using logistic
regression with or without adjustments for age, gender, BMI, and time
between examinations A and B.
Results: The levels of SF ARGS 18 years after meniscectomy ranged from
0.15 to 15.07 pmol/ml (mean 6.95 pmol/ml), were no different from levels
in un-operated individuals, and were unrelated to radiographic status at
examination A. A weak negative association was found between levels of SF
ARGS and loss of joint space: The likelihood of progression of radiographic
Table 1. Association of SF ARGS at examination A and progression of radiographic features
of OA from examination A to examination B 7.5 years later. Odds ratios (95% CI) adjusted
for age, gender, BMI and time between examinations A and B
Radiographic feature Total sample, Stratiﬁed for absence or presence
n=141 of ROA at examination A
No ROA, n=63 ROA, n=78
JSN 0.89 (0.79-0.996)* 0.77 (0.62-0.95)* 0.96 (0.81-1.13)
Osteophyte 0.97 (0.87-1.09) 0.92 (0.76-1.11) 0.99 (0.86-1.15)
ROA (JSN and/or Osteophyte) 0.89 (0.78-1.02) 0.87 (0.72-1.04) 0.91 (0.73-1.13)
*P<0.05.
